Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Transactions
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
bluebird bio, Inc. (BLUE) Create: Alert

All | News | Filings
Date FiledTypeDescription
09/27/2023 8-K Quarterly results
08/10/2023 4 Obenshain Andrew (President and CEO) has filed a Form 4 on bluebird bio, Inc.
Txns: Sold 16,929 shares @ $3.5416, valued at $60k
08/08/2023 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Sales Agreement, by and between bluebird bio, Inc. and Jefferies LLC",
"Opinion of Latham & Watkins, LLP"
08/08/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
08/08/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "CONFIDENTIAL 4 TO GIVE PATIENTS AND THEIR FAMILIES MORE BLUEBIRD DAYS"
08/08/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/08/2023 8-K Quarterly results
Docs: "bluebird bio Reports Second Quarter 2023 Financial Results and Highlights Operational Progress – Continued strong commercial launch for ZYNTEGLO® and SKYSONA®&#59; 16 patient starts across both programs to date –"
07/12/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Corporate Update by bluebird bio, Inc",
"Corporate Update by bluebird bio, Inc"
06/16/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
06/12/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "2023 NASDAQ: BLUE EXHIBIT 99.1"
06/06/2023 4 Klima Thomas J (See Remarks) has filed a Form 4 on bluebird bio, Inc.
Txns: Sold 4,130 shares @ $3.499, valued at $14.5k
05/09/2023 S-3 Form S-3 - Registration statement under Securities Act of 1933:
05/09/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/09/2023 8-K Quarterly results
Docs: "bluebird bio Reports First Quarter 2023 Financial Results and Highlights Operational Progress – Biologics License Application for lovo-cel for sickle cell disease submitted to FDA –"
04/28/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/28/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/21/2023 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
04/18/2023 PRE 14A Form PRE 14A - Other preliminary proxy statements:
04/05/2023 3 Paulson Richard A. (Director) has filed a Form 3 on bluebird bio, Inc.
04/05/2023 4 Paulson Richard A. (Director) has filed a Form 4 on bluebird bio, Inc.
Txns: Granted 4,663 shares @ $0
Granted 7,500 options to buy @ $3.3, valued at $24.8k
03/29/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
03/29/2023 10-K Annual Report for the period ended December 31, 2022
03/29/2023 8-K Quarterly results
03/10/2023 SC 13G/A STATE STREET CORP reports a 11% stake in AMENDED FILING BLUEBIRD BIO INC
03/09/2023 4 Leiderman Elisabeth (Director) has filed a Form 4 on bluebird bio, Inc.
Txns: Sold 1,004 shares @ $6.4643, valued at $6.5k
02/14/2023 SC 13G/A TANG CAPITAL PARTNERS LP reports a 5.6% stake in bluebird bio, Inc.
02/09/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/03/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
02/03/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
02/03/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
02/03/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
02/03/2023 SC 13G/A FIRST TRUST PORTFOLIOS LP reports a 0% stake in bluebird bio, Inc.
01/25/2023 SC 13G/A BlackRock Inc. reports a 8.9% stake in BLUEBIRD BIO INC
01/19/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy